Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
colorectal cancer
Biotech
Verastem CEO says RAS drug 'set new benchmark' for tricky cancer
Verastem Oncology's decision to refocus its R&D efforts on its KRAS inhibitor appears to be paying off based on initial data from a phase 1/2 trial.
Marissa Russo
Oct 14, 2026 10:27am
Abbott launches SimpleScreen CRC blood test in the US
Oct 2, 2026 2:17am
GSK pens $1.3B Hutchmed deal for KRAS-EGFR cancer asset
Sep 3, 2026 7:45am
BioNTech, Genentech cancel ph. 2 test of personalized cancer vax
Aug 28, 2026 1:50pm
PDS halts ph. 3 cancer therapy to focus on colorectal contender
Aug 13, 2026 9:55am
Guardant taps Patrick Dempsey for colorectal cancer awareness
Jul 28, 2026 8:54am